As the U.S. stock market navigates the complexities of a government shutdown and fluctuating employment figures, major indices like the Dow Jones have managed to shake off early declines, reflecting resilience amid uncertainty. In such times, investors often look beyond traditional stocks to explore opportunities in less conventional areas like penny stocks. While the term 'penny stocks' might seem outdated, these smaller or newer companies can offer a blend of affordability and growth potential when backed by solid financials. This article will highlight three promising penny stocks that stand out for their financial strength and potential for significant returns.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.07 | $445.75M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.89 | $698.01M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $1.16 | $222.33M | ✅ 4 ⚠️ 2 View Analysis > |
| Sensus Healthcare (SRTS) | $3.14 | $52.11M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.89 | $24.12M | ✅ 4 ⚠️ 2 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $77.45M | ✅ 2 ⚠️ 5 View Analysis > |
| Table Trac (TBTC) | $4.68 | $20.88M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.98 | $7.26M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.87 | $91.31M | ✅ 3 ⚠️ 2 View Analysis > |
| Universal Safety Products (UUU) | $3.99 | $9.9M | ✅ 2 ⚠️ 3 View Analysis > |
Click here to see the full list of 373 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Relmada Therapeutics (RLMD)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in the United States with a market cap of $62.40 million.
Operations: Relmada Therapeutics, Inc. does not report any revenue segments as it is a clinical-stage biotechnology company.
Market Cap: $62.4M
Relmada Therapeutics, with a market cap of US$62.40 million, is a pre-revenue clinical-stage biotech firm. Despite being debt-free and having short-term assets exceeding liabilities, it faces challenges including high volatility and less than one year of cash runway. The company's stock was transferred to the Nasdaq Capital Market after failing to meet the minimum bid price requirement but has until January 2026 to regain compliance. Recent appointments, like Dr. Yair Lotan as Chair of its Clinical Advisory Board, aim to bolster its strategic direction as it prepares for Phase 3 trials in bladder cancer treatment NDV-01.
- Dive into the specifics of Relmada Therapeutics here with our thorough balance sheet health report.
- Examine Relmada Therapeutics' earnings growth report to understand how analysts expect it to perform.
Definitive Healthcare (DH)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Definitive Healthcare Corp. offers a software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally, with a market cap of approximately $578.44 million.
Operations: The company generates revenue of $244.93 million from its Internet Information Providers segment.
Market Cap: $578.44M
Definitive Healthcare, with a market cap of US$578.44 million, operates within the SaaS healthcare commercial intelligence sector. Despite being unprofitable, it maintains a positive cash flow and has sufficient cash runway for over three years. The company's short-term assets exceed both its short and long-term liabilities, indicating financial stability. Recent earnings showed a reduction in net loss compared to the previous year, and management raised full-year revenue guidance slightly. However, challenges include an inexperienced management team with an average tenure of 0.8 years and increased debt-to-equity ratio over five years to 41.1%.
- Click here and access our complete financial health analysis report to understand the dynamics of Definitive Healthcare.
- Evaluate Definitive Healthcare's prospects by accessing our earnings growth report.
Seritage Growth Properties (SRG)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Seritage Growth Properties is a company focused on the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties across the United States with a market cap of $234.31 million.
Operations: The company generates revenue primarily through its real estate properties, amounting to $15.35 million.
Market Cap: $234.31M
Seritage Growth Properties, with a market cap of US$234.31 million, focuses on real estate development and management but remains unprofitable. Recent earnings revealed a narrowed net loss compared to the previous year, while revenue slightly increased to US$4.65 million for the second quarter of 2025. The company's short-term assets cover its short-term liabilities but fall short against long-term obligations. Despite sufficient cash runway for over a year and reduced debt-to-equity ratio from 158% to 56.7% over five years, challenges persist with negative return on equity and ongoing losses impacting financial performance.
- Get an in-depth perspective on Seritage Growth Properties' performance by reading our balance sheet health report here.
- Examine Seritage Growth Properties' past performance report to understand how it has performed in prior years.
Turning Ideas Into Actions
- Navigate through the entire inventory of 373 US Penny Stocks here.
- Looking For Alternative Opportunities? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Relmada Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com